| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.43 | 0.00 (0.00%) | 0.23 - 0.55 | 3.8 thousand (Below Avg) |
Market data as of 3:58PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 0.43 |
|---|---|
| Previous Close | 0.43 |
| Day's Range | 0.38 - 0.43 |
| Market Cap | 15.8M |
| Avg Volume (10 Day) | 32.0K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.24 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Fail |
Study Published in Journal of Dental Research Demonstrates Value of Genetics in Preventing Periodontal Disease
Business Wire - Monday 06/10/2013 11:32 AM ET
Interleukin Genetics to Discuss Corporate Update and First Quarter Results
Business Wire - Thursday 05/23/2013 4:05 PM ET
Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2013 Results
Business Wire - Monday 05/20/2013 12:00 PM ET
Interleukin Genetics Announces $12 Million Private Placement
Business Wire - Monday 05/20/2013 7:55 AM ET
| ILIU | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 10.59 |
| Company | Last | Change |
|---|---|---|
| ImmuCell Corp | 3.65 | -1.35% |
| Palatin Technologies Inc | 0.63 | -0.16% |
| Venaxis Inc | 1.32 | +3.94% |
| Chembio Diagnostics Inc | 4.92 | -1.38% |
| Vermillion Inc | 2.77 | -0.72% |
Data is delayed by at least 15 min.